Founded in 1983, Positron Corporation develops specialized PET and PET-CT molecular imaging systems with an emphasis on cardiac nuclear imaging. Its product line targets mid-sized hospitals and cardiology practices, offering cost-effective imaging solutions supported by comprehensive service and financing models. Despite recent revenue growth driven by strategic partnerships and emerging oncology applications, Positron remains unprofitable with substantial operating losses and cash flow deficits raising going concern doubts. The company aims to leverage a lower-cost value proposition against large equipment OEMs while navigating regulatory milestones and market adoption challenges.